GenWay Biotech Launches Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 2011 First Multiple Biomarker Test to Predict Near Term MI
FirstMark, the diagnostic division of GenWay Biotech, Inc., today announced study results and the commercial launch of PREventTM. FirstMark PREvent is the first multiple biomarker test that accurately predicts near term (approximately 2-3 years) risk of myocardial infarction for suspected or confirmed coronary artery disease (CAD) patients. FirstMark PREvent is now available and will be targeted to primary care physicians and cardiologists.
San Diego, CA, November 24, 2011 --(PR.com)-- FirstMark, the diagnostic division of GenWay Biotech, Inc., today announced study results and the commercial launch of PREventTM. FirstMark PREvent is the first multiple biomarker test that accurately predicts near term (approximately 2-3 years) risk of myocardial infarction for suspected or confirmed coronary artery disease (CAD) patients. FirstMark PREvent was launched, and the data from the phase I clinical study entitled, “Aggregate Risk Score Based on Markers of Inflammation, Immunity, and Thrombosis is an Independent Predictor of Adverse Cardiovascular Outcomes,” was presented Danny J. Eapen, MD, at the American Heart Association Scientific Sessions 2011 (AHA), in Orlando, Florida.
PREvent is a simple blood test based on technology developed and patented by GenWay, Emory University and MedStar. The test aggregates multiple biomarkers that identify the multiple pathways that lead to vulnerable plaques. Phase I and phase II clinical studies for the test were comprised of approximately 3,000 individuals with suspected or confirmed CAD. The studies showed PREvent to be significantly more powerful than other tests and risk factors, by identifying the top 10 percent of confirmed CAD patients that are at a 6.45 times higher risk of a near term MI within a 2-3 year period, as compared to other CAD patients. The test also proved to be 12 times more powerful than the single biomarker CRP. The remarkable results indicate that 18 percent of CAD patients with all three biomarkers elevated, as compared to two percent with zero biomarkers elevated, experienced an MI or cardiac death within one year.
PREvent is a critical advancement in cardiovascular medicine addressing the unmet need to access risk of near term MI. “This simple blood test is an exciting development for suspected or confirmed CAD patients, allowing physician’s diagnostic clarity in identifying CAD patients that are in most urgent need of aggressive treatment and monitoring,” said Thomas Silberg, President and CEO of GenWay Biotech. FirstMark PREvent is now available and will be targeted to primary care physicians and cardiologists.
The AHA Scientific Sessions 2011 abstract is available at: http://www.thefirstmark.com/wp-content/uploads/]2011/11/AHA_Abstract.pdf. Additional information about the test is available at http://www.FirstMarkPREvent.com
About GenWay Biotech, Inc.
GenWay Biotech, is comprised of three divisions. The FirstMark division is focused on the development and commercialization of non-invasive diagnostic and health monitoring tests for unmet clinical needs. GenWay’s catalog products and custom services divisions are focused on protein and antibody solutions. GenWay’s headquarters are located in the heart of San Diego’s biotech community in the Sorrento Valley/Mesa area.
###
PREvent is a simple blood test based on technology developed and patented by GenWay, Emory University and MedStar. The test aggregates multiple biomarkers that identify the multiple pathways that lead to vulnerable plaques. Phase I and phase II clinical studies for the test were comprised of approximately 3,000 individuals with suspected or confirmed CAD. The studies showed PREvent to be significantly more powerful than other tests and risk factors, by identifying the top 10 percent of confirmed CAD patients that are at a 6.45 times higher risk of a near term MI within a 2-3 year period, as compared to other CAD patients. The test also proved to be 12 times more powerful than the single biomarker CRP. The remarkable results indicate that 18 percent of CAD patients with all three biomarkers elevated, as compared to two percent with zero biomarkers elevated, experienced an MI or cardiac death within one year.
PREvent is a critical advancement in cardiovascular medicine addressing the unmet need to access risk of near term MI. “This simple blood test is an exciting development for suspected or confirmed CAD patients, allowing physician’s diagnostic clarity in identifying CAD patients that are in most urgent need of aggressive treatment and monitoring,” said Thomas Silberg, President and CEO of GenWay Biotech. FirstMark PREvent is now available and will be targeted to primary care physicians and cardiologists.
The AHA Scientific Sessions 2011 abstract is available at: http://www.thefirstmark.com/wp-content/uploads/]2011/11/AHA_Abstract.pdf. Additional information about the test is available at http://www.FirstMarkPREvent.com
About GenWay Biotech, Inc.
GenWay Biotech, is comprised of three divisions. The FirstMark division is focused on the development and commercialization of non-invasive diagnostic and health monitoring tests for unmet clinical needs. GenWay’s catalog products and custom services divisions are focused on protein and antibody solutions. GenWay’s headquarters are located in the heart of San Diego’s biotech community in the Sorrento Valley/Mesa area.
###
Contact
GenWay Biotech
Deborah Moore
858-458-0866
thefirstmark.com
Deborah Moore
858-458-0866
thefirstmark.com
Contact
Categories